Hot Investor Mandate: Large Pharma Company Seeks to In-License Novel Therapeutic Assets and Platforms in Orphan/Rare Disease Indications

16 Aug

A East Coast region-based large pharmaceutical specializes in the development of treatments for ultra-orphan diseases (diseases with under 20,000 patients in the USA or EU), and is seeking to in-license novel therapeutics and platforms in this space.

The firm is focused on serving patients and families affected by rare diseases. The firm focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: